STAT

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

No one know if this drug works. So doctors should avoid prescribing it, except perhaps to the most severely ill patients.

As the pandemic deepens, physicians face an agonizing decision — to medicate or not to medicate?

Here’s the dilemma: Over the past few weeks, some small studies suggested a decades-old malaria drug called hydroxychloroquine may have the potential to combat the novel coronavirus known as Covid-19. And as the results trickled out, the tablet has become more valuable than gold.

Prescriptions and jumped, causing shortages. State pharmacy boards, in fact, claimed some doctors were hoarding the medicine for themselves. President Trump touted the tablet by saying he had a “feeling” it would work. The widely watched conservative TV host Laura Ingraham tweeted that one seriously ill patient recovered like “Lazarus” after being

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related Books & Audiobooks